 price
cardin train toward
report beat rais pharma fundament
continu track well price volum front
specialti gener improv drive result
medic mix volum slower tougher
comp off-set improv profit gown recal cost
back look forward number
increas slower pharma margin declin even
account cah increas opioid litig cost
smaller contribut higher revenu growth given
higher estim increas price target
retain in-lin rate given valuat like cap
opioid overhang resolv
pleas see confer call note
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
voluntari recal free-sourc pack hospit gown
medic commerci suppli chain momentum slow bit due recal issu still
uncertain implic second half revenu profit implic
engag third parti expert monitor qualiti assur polici protocol
record mm charg result mm sg mm cog
reinvest strong b/ grow dividend would consid
work four state coordin state
remain talk global settlement opioid
paid mm lt debt paid mm
chang jurisdict mix aid tax rate
save program track hit mm target mm
share repo program repurchas mm share average valu per share
mm remain board author
outlook ep guid
addit clariti regard extern factor includ med devic tax tariff
brand inflat
expect pharma segment exceed fy expect
expect yoy improv
expect tougher yoy comp improv market fundament last year
opioid legal cost mm fy mm initi expect major
brand inflationwithin rang expect smaller contribut year
increas back half year
medicalcordi charg affect second half plan reduc debt least bn
pharma profit declin lsd origin expect low dd declin gener program
tw year
perform across compon see stronger industri dynam
red oak perform well servic level also greatimport
still see volum growth despit custom bankruptci store closur
earlier expect launch new item favor mix
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin februari
analyst elizabeth anderson suzi yoon amato primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
